Pharmaceutical R&D spending remains far below industry’s 10% commitment – PMPRB report

Mark Henderson
December 13, 2017

Another year of less-than-impressive R&D spending by the pharmaceutical industry has re-ignited the annual sparing match between industry and the organization that compiles the data. The Patented Medicines Prices Review Board (PMPRB) reports that companies belonging to Innovative Medicines Canada (IMC – formerly Rx&D) spent $770 million on R&D in 2016 or 4.9% of its $15.6 billion in sales – a ratio unchanged from 2015.

... Please become a Member or login to read the rest of this article ...


Other stories mentioning these organizations, people and topics
Organizations: Canadian Generic Pharmaceutical Association, Innovative Medicines Canada, and Patented Medicines Prices Review Board
People: Jim Keon and Pamela Fralick
Topics: phamaceutical R&D

Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 0 free articles remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.